Can a New Heat-Stable Hantavirus Vaccine Change Outbreak Preparedness?

A new heat-stable hantavirus vaccine could improve outbreak response and vaccine access in vulnerable regions.

Hantavirus infections have recently gained global attention following multiple international outbreaks and renewed concerns over rodent-borne diseases.

At the same time, scientists at the University of Bath are working on a next-generation vaccine that could change how future hantavirus outbreaks are managed (1^✔ ✔Trusted Source
The cutting-edge vaccine technology aiming to pandemic-proof the world

Go to source

).

The research team, led by Professor Asel Sartbaeva and the University spinout company EnsiliTech, is developing a new vaccine against Hantaan virus using mRNA technology combined with a heat-stabilizing process called “ensilication.”

Early laboratory and animal testing has shown strong immune responses, and researchers expect the vaccine to progress toward Phase 1 human clinical trials in the near future. According to the University of Bath, the platform is also being designed to remain b>stable without refrigeration, potentially improving vaccine access in remote and resource-limited regions.

Why Is a New Hantavirus Vaccine Needed So Urgently?

Hantaviruses are a group of rodent-borne RNA viruses that can cause severe illnesses such as Hemorrhagic Fever with Renal Syndrome (HFRS) and Hantavirus Pulmonary Syndrome (HPS).

The viruses are primarily transmitted through exposure to infected rodent urine, saliva, or droppings. Studies report that certain strains, particularly the Andes strain, may rarely spread between humans during prolonged close contact.

Although hantavirus infections are relatively uncommon globally, the diseases can be highly dangerous. According to BMJ, HPS may cause death in up to 50% of severe cases, while HFRS linked to Hantaan virus can have mortality rates ranging from 5% to 15% (4^✔ ✔Trusted Source
Hantavirus: What you need to know

Go to source).

Additional concerns come from the growing global burden of rodent-borne viruses.

A review published in the journal Viruses noted that rodents are reservoirs for nearly 60 zoonotic diseases and over 15,000 rodent-associated viruses have already been identified worldwide.

Researchers warned that urbanization, climate change, deforestation, and expanding human contact with rodent habitats are increasing the risk of future outbreaks (2^✔ ✔Trusted Source
The Hidden Threat: Rodent-Borne Viruses and Their Impact on Public Health

Go to source).

Despite these risks, no globally approved or widely available hantavirus vaccine currently exists, leaving prevention and supportive care as the primary public health strategies.

How Does This New Heat-Stable Vaccine Technology Work?

The experimental vaccine combines:

• mRNA vaccine engineering
• “Ensilication” thermal stabilization technology

The mRNA component is designed to trigger immune responses against Hantaan virus antigens. The second component — ensilication — is a patented technology developed at the University of Bath that surrounds vaccine materials with protective silica shells, helping stabilize them at room temperature.

This approach addresses one of the biggest limitations of current mRNA vaccines: dependence on ultra-cold storage. Many mRNA vaccines require temperatures as low as -70°C to -80°C during transport and storage.

According to the University of Bath team, failures in global cold-chain systems result in enormous vaccine waste every year, especially in low-resource regions where refrigeration infrastructure is unreliable.

Researchers believe a thermally stable platform could improve emergency response to outbreaks and expand vaccine access for vulnerable populations.

The researchers also suggest that once validated, the same heat-stable platform may eventually support vaccines against other infectious diseases and future pandemics.

Could Advanced Vaccine Design Improve Protection Against Multiple Strains?

Scientists are also exploring broader vaccine-design strategies to improve protection against different hantavirus strains.

A study published in PLOS ONE described computationally designed multi-epitope hantavirus vaccines targeting both envelope and nucleoprotein antigens.

Researchers used immune-informatics and molecular modeling approaches to identify highly antigenic T-cell and B-cell epitopes capable of generating strong immune responses (3^✔ ✔Trusted Source
In silico design of multi-epitope vaccines against the hantaviruses by integrated structural vaccinology and molecular modeling approaches

Go to source).

The study reported promising immune simulation results, including:

• Strong IgG and IgM antibody responses
• Activation of cytokines and interleukins
• Robust interaction with human Toll-like receptor 3 (TLR3)
• Favorable antigenic and non-allergenic profiles

Researchers noted that these vaccine constructs still require laboratory and clinical validation, but the findings highlight how artificial intelligence, bioinformatics, and structural vaccinology are increasingly being used to accelerate vaccine development for emerging infectious diseases.

What Makes Hantavirus Outbreaks Difficult to Control?
Hantavirus outbreaks are difficult to detect early because symptoms initially resemble common viral infections before rapidly progressing into severe disease.

According to BMJ, early symptoms may include:

• Fever
• Headache
• Muscle pain
• Vomiting
• Fatigue

In severe cases, patients may develop:

• Kidney failure
• Internal bleeding
• Severe respiratory distress
• Pulmonary edema
• Shock

The recent 2026 international cruise ship outbreak linked to the Andes strain renewed global concern over hantavirus preparedness and highlighted the lack of effective vaccines or approved antiviral therapies.

Public health experts also warn that increasing environmental disruption and changing ecological conditions may continue to raise the risk of rodent-borne disease transmission in the future.

How Close Is the Vaccine to Human Trials?

The vaccine remains experimental and has not yet entered human clinical trials.
So far, the University of Bath team reports promising immune responses in laboratory and animal testing, with Phase 1 clinical trials expected in the near future.

The project is being developed with support from the UK Vaccine Network in collaboration with international partners in South Africa and the United States.

Researchers believe the combination of mRNA science and heat-stable vaccine technology could eventually become an important tool for outbreak preparedness, particularly in regions where maintaining cold-chain storage remains difficult.

References:

1. The cutting-edge vaccine technology aiming to pandemic-proof the world – (https://www.bath.ac.uk/announcements/the-cutting-edge-vaccine-technology-aiming-to-pandemic-proof-the-world/)
2. The Hidden Threat: Rodent-Borne Viruses and Their Impact on Public Health – (https://pmc.ncbi.nlm.nih.gov/articles/PMC12197361/)
3. In silico design of multi-epitope vaccines against the hantaviruses by integrated structural vaccinology and molecular modeling approaches – (https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0305417)
4. Hantavirus: What you need to know – (https://www.bmj.com/content/393/bmj.s877)

Source-Medindia